China Chemical & Pharmaceutical Co., Ltd.

As of June 30, 2024, China Chemical & Pharmaceutical Co., Ltd. has 298.08M shares outstanding.

As of June 30, 2024, China Chemical & Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 18.71. The price-to-sales ratio is 0.75, and the price-to-book ratio stands at 1.11.

As of June 30, 2024, China Chemical & Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 28.27 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 28.27 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. China Chemical & Pharmaceutical Co., Ltd. trades at an EV/FCF ratio of 9.24, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2024, China Chemical & Pharmaceutical Co., Ltd. maintains a current ratio of 1.47, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.75, indicating elevated leverage, while an interest coverage ratio of 5.16 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2024, China Chemical & Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 6.03, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.50 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.81, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.50, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.22 indicates how many times China Chemical & Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended June 30, 2024. That works out to an effective tax rate of 19.83, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on September 3, 2024, China Chemical & Pharmaceutical Co., Ltd.'s stock has declined approximately 10.00% over the past 52 weeks. The 50-day moving average sits at 21.84, while the 200-day moving average is 22.89.

Over the twelve months ended June 30, 2024, China Chemical & Pharmaceutical Co., Ltd. posted a gross margin of 36.79, reflecting its pricing power and cost economics. The operating margin of 3.71 and net profit margin of 4.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield stands at 14.37, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.83, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to China Chemical & Pharmaceutical Co., Ltd. shareholders.

China Chemical & Pharmaceutical Co., Ltd.'s most recent stock split took place on July 26, 2005 with a 10:11 split ratio.

As of June 30, 2024, China Chemical & Pharmaceutical Co., Ltd. has an Altman Z-Score of 2.07, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.